Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Rating of “Moderate Buy” from Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $41.75.

A number of brokerages have weighed in on COAG. Jefferies Financial Group began coverage on Hemab Therapeutics in a research report on Tuesday. They set a “buy” rating and a $39.00 price target on the stock. The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a research report on Tuesday. They set a “buy” rating and a $36.00 price target on the stock. Wedbush initiated coverage on Hemab Therapeutics in a report on Tuesday. They set an “outperform” rating and a $42.00 price objective for the company. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday. Finally, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

Insider Activity

In other news, major shareholder Ra Capital Management, L.P. acquired 3,802 shares of Hemab Therapeutics stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $24.97 per share, for a total transaction of $94,935.94. Following the completion of the acquisition, the insider directly owned 6,375,972 shares in the company, valued at approximately $159,208,020.84. The trade was a 0.06% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders purchased a total of 2,902,872 shares of company stock worth $53,769,784 in the last three months.

Hemab Therapeutics Price Performance

Shares of NASDAQ COAG opened at $28.00 on Friday. Hemab Therapeutics has a twelve month low of $23.00 and a twelve month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.